Navigation Links
Integrated BioPharma's Proprietary Vaccine Technology Achieves,Strong Positive Results

unique grouping of companies presently serving the varied needs of the health care industry. Through its nutraceutical business, the Company creates, develops, manufactures and markets products worldwide. The Company’s biotechnology business uses its patented plant-based technology to produce vaccines and therapeutic antibodies. Its pharmaceutical business operates a cGMP facility for the production and sale of Paclitaxel and related drugs and provides technical services through its contract research organization. Further information is available at www.iBioPharma.com.

Statements included in this release related to Integrated BioPharma, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential risk factors that could affect the company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.

Contact: Jeffery Leach, VP Dina Masi, CFO Integrated BioPharma Inc 888-319-6962 d.masi@ibiopharma.com


'"/>




Page: 1 2

Related medicine technology :

1. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
2. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
3. Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials
4. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
5. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
6. Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting
7. Neurogen Proprietary Insomnia Compound Data Presented at Associated Professional Sleep Societies Annual Meeting
8. Neurogen Proprietary Insomnia Compound Data Presented at American Psychiatric Association Annual Meeting
9. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
10. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
11. Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention
Post Your Comments:
(Date:9/16/2014)... -- On September 25 to 26, 2014, ... and manufacturing - MEDTEC China  - will mark its ... Convention Center, bringing together close to 300 leading global ... latest medical-grade raw materials, parts and processing technologies. ... free visitor pre-registration to be completed. To date, more ...
(Date:9/16/2014)... , Sept. 16, 2014 Northwest Biotherapeutics (NASDAQ: ... developing DCVax® personalized immune therapies for solid tumor cancers, ... to receive formal designation as a "Promising Innovative Medicine" ... (EAMS) launched in the UK in April 2014.  A ... for early access approval under the EAMS.  ...
(Date:9/16/2014)... 2014  Synereca Pharmaceutics, Inc. (SPI), a ... drugs that restore or increase the effectiveness ... million convertible debt financing. Accele Venture Partners, ... Accele Biopharma, Inc., led the financing with ... private not-for-profit corporation focused on growing innovative ...
Breaking Medicine Technology:MEDTEC China 2014: Seven Highlights Not to Miss! 2MEDTEC China 2014: Seven Highlights Not to Miss! 3MEDTEC China 2014: Seven Highlights Not to Miss! 4NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 2NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 3NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 4NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 5Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 3Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 4
... France, July 10 Ipsogen SA,(Alternext: ALIPS) today reported ... Therapy of Early Breast Cancer indicated for the first,time ... adjunct to the,histological grade. These new guidelines, published online ... European and US experts on,early breast cancer treatment that ...
... , KENILWORTH, N.J., July 9 Schering-Plough Corporation (NYSE: ... the company,s country operation in Japan, has received marketing ... for the treatment of bronchial asthma in adults.(1) , ... of the ASMANEX TWISTHALER in Japan," said Thomas P. ...
Cached Medicine Technology:Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer 2Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer 3ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients 2ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients 3ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients 4
(Date:9/16/2014)... the right balance of nitrogen, phosphorus and potassium is ... State University study finds. , A review of data ... other regions showed that high yields were linked to ... nutrients at specific ratios - nitrogen and phosphorus at ... a ratio of 1-to-1. These nutrient uptake ratios were ...
(Date:9/16/2014)... PA (PRWEB) September 16, 2014 AcousticSheep ... are preparing to launch RunPhones® Wireless, their latest version ... inside a sport-style headband for active people seeking a ... sport headphones on the market and will be ... new RunPhones® Wireless has all of the same great ...
(Date:9/16/2014)... Tara Haelle HealthDay ... -- About 14.5 million U.S. cancer survivors are alive ... American Association for Cancer Research reported Tuesday. These ... include nearly 380,000 survivors of childhood cancer, according to ... in prevention, identification, research and treatment of cancer and ...
(Date:9/16/2014)... September 16, 2014 Novatus, a leading ... new office in London, UK, and appointed Jim Curran ... Europe, the expansion will allow Novatus to target growing ... European customers. , “Novatus is excited ... London is an ideal location to establish our European ...
(Date:9/16/2014)... DC September 16, 2014 The ... coherence tomography (OCT) in primary percutaneous coronary ... annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. ... TCT is the world,s premier educational meeting ... OCT uses light emitted from an intravascular ...
Breaking Medicine News(10 mins):Health News:Boosting global corn yields depends on improving nutrient balance 2Health News:Boosting global corn yields depends on improving nutrient balance 3Health News:RunPhones® Prepares to Launch Their New Highly Anticipated Wireless Headphones 2Health News:RunPhones® Prepares to Launch Their New Highly Anticipated Wireless Headphones 3Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 2Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 3Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 4Health News:Novatus Expands European Operations with a New Office in London 2Health News:Results of OCT STEMI trial reported at TCT 2014 2
... , SEATTLE, Aug. 24 Cell Therapeutics, Inc. (CTI) ... Drug Administration (FDA) has accepted and has filed for review the ... or refractory aggressive non-Hodgkin,s lymphoma (NHL). A Prescription Drug User Fee ... review of the pixantrone NDA by September 4th 2009. ...
... at the time of diagnosis do not live as long ... conclusion of a new study to be published in the ... journal of the American Cancer Society. The authors of the ... marital separation may compromise an individual,s immune system and lead ...
... factor for active tuberculosis (TB) disease, according to a new ... analyzed data from nearly 17,000 individuals in Taiwan as part ... past studies have reported increased mortality among TB patients who ... effect of smoking on active TB incidence using a longitudinal ...
... A new technique may help clinicians hone in on a ... cause. The study, led by principal investigator Y.C. ... the American Thoracic Society,s American Journal of Respiratory and ... of fluid in the pleural cavity, can be maddeningly difficult ...
... Over one-hundred business ... , ... -- Rooted in Newtonian and quantum science, ancient spiritual and healing traditions, and clinical studies, ... book ColorAlchemy , by Jami Lin teaches people how to harness a daily color ...
... diagnosis of Idiopathic Pulmonary Fibrosis is not much better ... the survival rate is less than three years. ... that targeting of a novel gene utilizing genetic and ... mice and will be developed for future testing in ...
Cached Medicine News:Health News:FDA Accepts to File Cell Therapeutics' New Drug Application for Pixantrone 2Health News:FDA Accepts to File Cell Therapeutics' New Drug Application for Pixantrone 3Health News:Cancer patients who are separated when diagnosed have worse survival rates 2Health News:Smoking increases risk of developing active TB 2Health News:Smoking increases risk of developing active TB 3Health News:New technique can help diagnose mesothelioma 2Health News:Business Association in Denver Invites Award-winning Author of ColorAlchemy to Provide Motivation to Energize Performance and Stimulate Success Using the Color Red 2Health News:Business Association in Denver Invites Award-winning Author of ColorAlchemy to Provide Motivation to Energize Performance and Stimulate Success Using the Color Red 3Health News:Business Association in Denver Invites Award-winning Author of ColorAlchemy to Provide Motivation to Energize Performance and Stimulate Success Using the Color Red 4Health News:U-M researchers discover therapeutic target that could help patients with pulmonary fibrosis 2
... System is a point-of-care system designed for ... referred to as Platelet Rich Plasma - ... a small sample of blood. The Symphony ... factors, which are found in the platelets. ...
... Dual Imaging Color Module Leica combines precision microscopy ... important and necessary patient data can be displayed ... optical platform on the Leica OH3, OHS1, MS3 ... highest brightness, contrast >300:1, true color and resolution ...
... Headlight mounted micro video camera has ... pictures in areas otherwise invisible to all ... capabilities. The system may be used for ... eliminating crowding of the sterile area and ...
... DXC-S500 consists of 2-piece body, one is CHU ... and built-in Peltier cooling devices, the other is ... monitor. CCU incorporates IEEE1394 interface for direct connection ... card slot for storing images into memory stick ...
Medicine Products: